
Tavo Biotherapeutics Announces Appointment of Seasoned Executives to Key Posts
---- Additions to senior team will drive Tavo's strategy to develop new innovative therapeutics addressing critical unmet needs in glaucoma and retinal disease
IRVINE, Calif. , April 29, 2025 /PRNewswire/ -- Tavo Biotherapeutics, a leading innovator in the ophthalmology industry, today announced the appointment of Lukas Scheibler, Ph.D. as Chief Research and Development Officer, and Graham Cooper as Chief Financial Officer. Both bring proven track records of success in the biotechnology industry.
'I am thrilled to bring on Lukas and Graham to Tavo's senior team,' said Gary Berman, Chief Executive Officer. 'Lukas has had an illustrious career in ophthalmology, from introducing Lucentis in Europe for Novartis, running clinical development at Alcon, and pioneering the development of Syfovre for geographic atrophy at Apellis. He is a recognized leader in the industry, and he will play a central role in driving our clinical and pre-clinical programs in treatments for glaucoma and retinal disease.'
Berman continued, 'Likewise, Graham has extensive experience in the biotech field, across multiple therapeutic indications. Throughout his career he has raised over a billion dollars in capital, having taken companies public and scaled enterprises from the early stages, hiring teams and managing growth. He is a recognized leader in the venture capital and public investor communities and brings a wealth of experience and strong relationships to Tavo. Lukas and Graham fill pivotal roles for Tavo, and they join us at a key time as we prepare to raise capital and advance our pipeline into the clinic. Attracting these accomplished executives builds on our momentum in developing breakthrough therapies that address fundamental unmet needs in ophthalmology.'
Dr. Lukas Scheibler was most recently Chief Innovation Officer at Apellis. In this role, he was responsible for all research and development activities through human proof of concept. Prior to that, he was Head of Clinical Development at Alcon, where he was responsible for the planning and execution of all clinical trials. Dr. Scheibler began his career in ophthalmology in research and development at Novartis, where he played a key role in the in-licensing and approval of Lucentis in Europe. He holds a Ph.D. from the University of Lausanne, Switzerland, and completed postdoctoral training at Harvard Medical School.
Graham Cooper was Chief Financial Officer for Receptos, which he joined prior to its IPO. At Receptos, he played a key role in managing through a dramatic growth phase and raising capital, culminating in its sale to Celgene for $7.8 billion. He also served as Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, developing innovative anti-viral therapies for the treatment of HBV, as well as other private and public biotechnology companies. Prior to his operating roles, Mr. Cooper held positions of increasing responsibility at Deutsche Bank Securities, including Director, Health Care Investment Banking. He began his career at Deloitte & Touche and was previously a CPA. Mr. Cooper currently serves as a member of the board of Beam Therapeutics (BEAM) and chairman of the board of Kezar Life Sciences (KZR). Mr. Cooper received a BA in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business.
About Tavo Biotherapeutics
Tavo Biotherapeutics is developing innovative new treatments to address critical unmet needs in ophthalmology. TAV-001 is being developed for the treatment of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown substantial reduction in intraocular pressure, as well as signals of neuroprotection, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic macular edema and diabetic retinopathy, as well as both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.
Media Contact:
Graham Cooper
Chief Financial Officer
[email protected]
www.tavobio.com
View original content: https://www.prnewswire.com/news-releases/tavo-biotherapeutics-announces-appointment-of-seasoned-executives-to-key-posts-302441252.html
SOURCE Tavo Biotherapeutics

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Arvinas, Inc. (ARVN): A Bull Case Theory
This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish thesis on Arvinas, Inc. on by Ray Palmer. In this article, we will summarize the bulls' thesis on ARVN. Arvinas, Inc.'s share was trading at $7.59 as of July 16th. Photo by Myriam Zilles on Unsplash Arvinas (ARVN) presents a compelling deep value investment, trading at $6.50 despite holding $954M in cash ($13/share), significantly exceeding its market cap. Beyond cash, Arvinas owns a Novartis-partnered asset that brought in $150M upfront, with a risk-adjusted NPV estimated at $300M ($4/share). Its breast cancer drug, vepdegestrant (vepdeg), though no longer a blockbuster candidate, retains meaningful value as a second-line treatment for mutant patients—a smaller but high-value market. The company estimates a sum-of-the-parts valuation north of $20/share, though corporate overhead currently drags on that value. The opportunity exists due to a combination of investor disillusionment and strategic missteps. Vepdeg's Phase 3 data, announced in March, showed no efficacy in wild-type patients, capping its commercial scope. Pfizer, Arvinas's partner, subsequently cancelled combo trials, but notably retained involvement through a Phase 1 combo study it fully funds and prominently featured vepdeg in its ASCO plans—suggesting continued interest. A near-term catalyst is ASCO's full data reveal, where Arvinas has teased best-in-class potential in mutant breast cancer. A second catalyst could be Pfizer assuming full commercialization duties under existing partnership terms, avoiding Arvinas's inefficient standalone approach. If Pfizer declines, selling the asset becomes the most viable path. Activism remains a third catalyst. Insider ownership is minimal, executive compensation is excessive, and the cost structure hasn't adapted to the company's diminished scope. An activist could drive governance reforms, prevent value-destructive commercialization attempts, and push for a return of excess cash to shareholders. With a large margin of safety and multiple catalysts, Arvinas offers an attractive asymmetric risk/reward setup. Previously we covered a on Relay Therapeutics, Inc. by Steve Wagner in May 2025, which highlighted the company's strategic pivot to focus solely on RLY-2608, supported by deep cost cuts and a strong cash runway through 2029. The company's stock price has appreciated approximately by 15% since our coverage. This is because early clinical data validated RLY-2608's potential. The thesis still stands as the lead program advances into pivotal trials. Ray Palmer shares a similar view on the breast cancer space but emphasizes Arvinas's undervaluation, cash-rich balance sheet, and activist-driven upside. Arvinas, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held ARVN at the end of the first quarter which was 32 in the previous quarter. While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None.
Yahoo
3 days ago
- Yahoo
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data